Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Pharma M&A

<< Previous

Bullboard Posts

Next >>

Comment by Yellowknifer69on Jun 27, 2023 1:58pm

290 Views

Post# 35516804

RE:RE:RE:Pharma M&A

Hello and good afternoon Fellow ATE longs

Totally agree with Harper on his comment. A whole lot of no news happening around here. I was young when I bought this stock but might as well sign up for Long Term Care the way things are 'progressing' at Antibe. LoL

Oh well, a couple more years of waiting won't hurt either.

Yellowknifer

<< Previous

Bullboard Posts

Next >>

E3 inches closer to Alberta's first lithium production plant